Search results for " transplantation."

showing 10 items of 1389 documents

IL-17 controls central nervous system autoimmunity through the intestinal microbiome

2021

Interleukin-17A- (IL-17A) and IL-17F-producing CD4(+) T helper cells (T(H)17 cells) are implicated in the development of chronic inflammatory diseases, such as multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE). T-H 17 cells also orchestrate leukocyte invasion of the central nervous system (CNS) and subsequent tissue damage. However, the role of IL-17A and IL-17F as effector cytokines is still confused with the encephalitogenic function of the cells that produce these cytokines, namely, T-H 17 cells, fueling a long-standing debate in the neuroimmunology field. Here, we demonstrated that mice deficient for IL-17A/F lose their susceptibility to EAE, which…

0301 basic medicineCentral Nervous SystemMaleEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisreceptorImmunologyCentral nervous system610 Medicine & healthGut flora10263 Institute of Experimental Immunologymedicine.disease_causeAutoimmunityinterleukin-1703 medical and health sciencesMice0302 clinical medicinemedicinecytokineAnimalsHumanscnst-cellsMice Knockout2403 Immunologybiologygut microbiotaMultiple sclerosisExperimental autoimmune encephalomyelitisGeneral MedicineFecal Microbiota Transplantationneutralizationmedicine.diseasebiology.organism_classificationAdoptive Transfer3. Good healthGut EpitheliumGastrointestinal Microbiome030104 developmental biologyNeuroimmunologymedicine.anatomical_structureImmunology2723 Immunology and Allergy570 Life sciences; biologyTh17 CellssequencesFemaleInterleukin 17030217 neurology & neurosurgery
researchProduct

Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit

2020

Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with an established benefit for patients suffering from primary biliary cholangitis (PBC). It was first introduced in the 60s and took until the late 90s to demonstrate a survival benefit in large meta-cohort studies.1 Since then, UDCA is the established first-line therapy according to current guidelines.2 The benefit of UDCA is multidimensional, and patients receiving UDCA experience increased transplant-free survival, a decreased risk of hepatocellular carcinoma and potentially improved quality of life.3–5 The survival benefit is predicted by a number biochemical markers that reflect cholestasis and that are accepted surrogates of the…

0301 basic medicineCholagogues and Cholereticsmedicine.medical_specialty2312Cholangitismedicine.drug_classBiliary cirrhosisclinical decision makingliverGastroenterologyhepatobiliary disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePrimary biliary cirrhosisCholestasisInternal medicinemedicineHumans1506BezafibrateHepatologyBile acidLiver Cirrhosis Biliarybusiness.industryUrsodeoxycholic AcidGastroenterologyObeticholic acidmedicine.diseaseUrsodeoxycholic acidLiver Transplantationprimary biliary cirrhosis030104 developmental biologychemistryHepatocellular carcinoma030211 gastroenterology & hepatologybusinessmedicine.drugGut
researchProduct

Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus …

2016

Preemptive antiviral therapy for active CMV infection in allogeneic stem cell transplant recipients guided by immunological and virological parameters minimizes the risk of recurrent viremia in a subset of patients.

0301 basic medicineCongenital cytomegalovirus infectionViremiaContext (language use)DiseaseMajor Articles03 medical and health sciences0302 clinical medicineInterferonImmunityallogeneic stem cell transplantationimmunological monitoringMedicineIFN-γ CD8+ T cellscytomegalovirusbusiness.industryvirus diseasesmedicine.disease030104 developmental biologyInfectious DiseasesOncologypreemptive antiviral therapyImmunologyStem cellbusinessCD8030215 immunologymedicine.drugOpen forum infectious diseases
researchProduct

Non-cognate bystander cytolysis by clonal epitope-specific CTL lines through CD28-CD80 interaction inhibits antibody production: A potential caveat t…

2015

Abstract Adoptive transfer of virus epitope-specific CD8 T cells is an immunotherapy option to control cytomegalovirus (CMV) infection and prevent CMV organ disease in immunocompromised solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) recipients. The therapy aims at an early, selective recognition and cytolysis of infected cells for preventing viral spread in tissues with no adverse immunopathogenic side-effects by attack of uninfected bystander cells. Here we describe that virus epitope-specific, cloned T-cell lines lyse target cells that present the cognate antigenic peptide to the TCR, but simultaneously have the potential to lyse uninfected cells expressing…

0301 basic medicineCytotoxicity ImmunologicAdoptive cell transfermedicine.medical_treatmentImmunologyCytomegalovirusEpitopes T-Lymphocytechemical and pharmacologic phenomenaBiologyImmunotherapy AdoptiveEpitope03 medical and health sciencesMiceCD28 AntigensmedicineCytotoxic T cellAnimalsB-LymphocytesHematopoietic Stem Cell TransplantationCD28hemic and immune systemsImmunotherapyBystander EffectOrgan TransplantationVirologyClone CellsTransplantationCytolysis030104 developmental biologyAntibody FormationCytomegalovirus InfectionsB7-1 AntigenCD80T-Lymphocytes CytotoxicCellular immunology
researchProduct

STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity

2020

Natural killer (NK) cells are important components of the innate immune defense against infections and cancers. Signal transducer and activator of transcription 1 (STAT1) is a transcription factor that is essential for NK cell maturation and NK cell-dependent tumor surveillance. Two alternatively spliced isoforms of STAT1 exist: a full-length STAT1α and a C-terminally truncated STAT1β isoform. Aberrant splicing is frequently observed in cancer cells and several anti-cancer drugs interfere with the cellular splicing machinery. To investigate whether NK cell-mediated tumor surveillance is affected by a switch in STAT1 splicing, we made use of knock-in mice expressing either only the STAT1α (S…

0301 basic medicineCytotoxicity ImmunologicLymphomaNK cellsCell MaturationMice0302 clinical medicineInterferonImmunology and AllergyProtein IsoformsSTAT1Immunologic SurveillanceOriginal ResearchBone Marrow TransplantationReceptors InterferonInterleukin-15Mice KnockoutLymphopoiesisinterferonInterferon-Stimulated Gene Factor 3Cell biologySpecific Pathogen-Free OrganismsKiller Cells NaturalSTAT1 Transcription FactorOrgan SpecificityMHC class ISignal transductionsignal transductionmedicine.druglcsh:Immunologic diseases. AllergyLymphoid TissueImmunologyBiologyLymphocyte Depletion03 medical and health sciencesInterleukin-15 Receptor alpha SubunitCell Line TumormedicineAnimalsTranscription factorInnate immune systemisoformsMice Inbred C57BL030104 developmental biologyCancer cellSTAT proteinbiology.proteinlcsh:RC581-607IL-15RαSpleen030215 immunologyFrontiers in Immunology
researchProduct

2017

Better identification of severe acute graft-versus-host disease (GvHD) may improve the outcome of this life-threatening complication of allogeneic hematopoietic stem cell transplantation. GvHD induces tissue damage and the release of damage-associated molecular pattern (DAMP) molecules. Here, we analyzed GvHD patients (n = 39) to show that serum heat shock protein glycoprotein 96 (Gp96) could be such a DAMP molecule. We demonstrate that serum Gp96 increases in gastrointestinal GvHD patients and its level correlates with disease severity. An increase in Gp96 serum level was also observed in a mouse model of acute GvHD. This model was used to identify complement C3 as a main partner of Gp96 i…

0301 basic medicineDampchemistry.chemical_classificationbusiness.industrymedicine.medical_treatmentGeneral MedicineHematopoietic stem cell transplantationmedicine.diseaseIn vitro3. Good healthComplement system03 medical and health sciences030104 developmental biologyGraft-versus-host diseasechemistryIn vivoHeat shock proteinImmunologymedicinebusinessGlycoproteinJCI Insight
researchProduct

Stem cell therapy. Old challenges and new solutions

2020

Stem cell therapy (SCT), born as therapeutic revolution to replace pharmacological treatments, remains a hope and not yet an effective solution. Accordingly, stem cells cannot be conceivable as a "canonical" drug, because of their unique biological properties. A new reorientation in this field is emerging, based on a better understanding of stem cell biology and use of cutting-edge technologies and innovative disciplines. This will permit to solve the gaps, failures, and long-term needs, such as the retention, survival and integration of stem cells, by employing pharmacology, genetic manipulation, biological or material incorporation. Consequently, the clinical applicability of SCT for chro…

0301 basic medicineEngineeringmedicine.medical_treatmentbio-nanotechnologyregenerative medicineexosomesBio nanotechnologyRegenerative medicinestem cell therapystem cell transplantationEffective solution03 medical and health sciences0302 clinical medicinestem cellsBiological propertyGeneticsmedicine3D system3D systemshumansMolecular Biologybusiness.industry3D systems; bio-nanotechnology; bioprinting; exosomes; regenerative medicine; stem cell therapy; humans; regenerative medicine; stem cell transplantation; stem cellsGeneral MedicineStem-cell therapyExosome030104 developmental biology030220 oncology & carcinogenesisStem cellbusinessStem cell biologyNeurosciencebioprinting
researchProduct

Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review

2016

In recent years, umbilical cord blood (UCB) has been widely used as an alternative source to bone marrow (BM) for transplantation of hematopoietic stem and progenitor cells (HSPCs) in a variety of hematological and non-hematological disorders. Nevertheless, the insufficient number of UCB-HSPCs for graft represents a major challenge. HSPCs ex vivo expansion prior to transplantation is a valid strategy to overcome this limit. Several attempts to optimize the expansion conditions have been reported, including the use of mesenchymal stromal cells (MSCs) as feeder layer. Wharton's Jelly (WJ), the main component of umbilical cord (UC) matrix, is especially rich in MSCs, which are considered ideal…

0301 basic medicineFeeder CellSettore BIO/17 - IstologiaCancer ResearchStromal cellBone marrow transplantationCell Culture TechniquesEx vivo expansionFeeder layerBiology03 medical and health sciencesFeeder LayerWharton's jellymedicineHumansWharton JellyProgenitor cellCoculture TechniqueWharton’s jelly mesenchymal stromal cellCell ProliferationUmbilical cord blood transplantationMesenchymal Stromal CellMesenchymal stem cellHematopoietic Stem Cell TransplantationFeeder CellsMesenchymal Stem CellsCell DifferentiationHematopoietic Stem CellCell BiologyHematopoietic Stem CellsCoculture TechniquesCell biologyTransplantation030104 developmental biologymedicine.anatomical_structureImmunologyHematopoietic and progenitor stem cellBone marrowStem cellCell Culture TechniqueHuman
researchProduct

Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

2019

Background & Aims: Fibrosis progression (FP) after liver transplantation (LT) increases morbidity and mortality. Biomarkers are needed for early prediction of FP. A recipient’s seven-gene cirrhosis risk score (CRS) has been associated with FP, especially in non-transplant cohorts. A broader validation of CRS, including the genotype of the donor-organ and HCV-negative patients is lacking. We therefore analyzed the impact of donor- and recipient-specific genotypes on FP after LT in a large cohort of HCV-positive and -negative patients.Method: Genotyping from liver biopsies (n=201 donors) and peripheral blood (n=442 recipients) was performed. Cirrhosis risk score was correlated with FP at …

0301 basic medicineGenetic MarkersLiver CirrhosisMalemedicine.medical_specialtyCirrhosisTime Factorsmedicine.medical_treatmentLiver transplantationGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisRisk FactorsInternal medicineGenotypeotorhinolaryngologic diseasesMedicineHumansCumulative incidenceGenetic Predisposition to DiseaseFramingham Risk Scorebusiness.industryHazard ratioGastroenterologyMiddle Agedmedicine.diseaseTissue DonorsLiver Transplantation030104 developmental biologyPhenotypeTreatment OutcomeDisease Progression030211 gastroenterology & hepatologyFemalebusinessRisk assessmentJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Treatment strategies for lysosomal storage disorders.

2017

Over the past several years the number of treatments available for patients with lysosomal storage disorders has rapidly increased. Haematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction, and chaperone therapies are currently available, and gene therapies and other treatments are rapidly advancing. Despite remarkable advances, the efficacy of most of these therapies is limited, particularly because the treatments are usually initiated when organ damage has already occurred. To circumvent this limitation, screening in newborn infants for lysosomal storage disorders has been introduced in many countries. However, this screening is complicated by the broad cl…

0301 basic medicineGenetic enhancementLysosomal storage disordersBioinformatics03 medical and health sciences0302 clinical medicineDevelopmental NeuroscienceSlow progressionMedicineHumansEnzyme Replacement Therapybusiness.industryHematopoietic Stem Cell TransplantationEnzyme replacement therapyGenetic TherapyOrgan damageTransplantationLysosomal Storage Diseases030104 developmental biologyPediatrics Perinatology and Child HealthImmunologyTreatment strategyNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryMolecular ChaperonesDevelopmental medicine and child neurology
researchProduct